Clinical trials: Plasma Cell Neoplasm
Multiple Myeloma, Myeloma
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36…
- Conditions
- Multiple Myeloma, Myeloma, Myeloma Multiple
- Trial name
- NCT05651932
- Testing
- Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 165 people
- Sponsor
- K36 Therapeutics, Inc.
Multiple Myeloma
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma.
- Trial name
- NCT04649359
- Testing
- Elranatamab (PF-06863135)
- Where
- 78 sites in United States, Australia and 8 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Relapsed/Refractory Multiple Myeloma, Multiple Myeloma
A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
This is a Phase 4, multicenter, open-label, single-arm study evaluating the safety and efficacy of elranatamab monotherapy in adult participants with relapsed or refractory multiple myeloma in India.
- Trial name
- NCT07881835
- Testing
- Elranatamab
- Volunteers
- 75 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care…
- Conditions
- Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT05745285
- Testing
- LLS Program
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Miami
Myeloma
Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
The main goal of the project is to characterize the bone marrow immunological milieu and investigate potential treatment defining events of the tumor microenvironment in relapsed and refractory multiple myeloma (RRMM) patients…
- Trial name
- IMPACT (NCT07878208)
- Where
- 7 sites in Denmark, Norway
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital
Myeloma
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma…
- Trial name
- NCT04680468
- Testing
- Belantamab mafodotin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Graft-versus-leukemia, Graft vs Host Disease
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center.
- Conditions
- Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection
- Trial name
- NCT00106925
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Smoldering Multiple Myeloma
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: Lenalidomide Citarinostat (CC-96241) PVX-410
- Trial name
- NCT02886065
- Testing
- Hiltonol, Citarinostat, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Breast Neoplasm, Colorectal Neoplasm
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
This trial studies how well a decision aid website works in helping to make decisions about fertility in participants with cancer.
- Conditions
- Breast Neoplasm, Colorectal Neoplasm, Female Reproductive System Neoplasm, Health Care Provider
- Trial name
- NCT03141437
- Testing
- Best Practice, Educational Intervention, Internet-Based Intervention
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- M.D. Anderson Cancer Center
Newly Diagnosed Multiple Myeloma
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible.
- Trial name
- NCT04052880
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Larysa Sanchez
Myeloma, Multiple Myeloma
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.
- Conditions
- Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT06518551
- Testing
- Elotuzumab, Iberdomide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Omar Nadeem, MD
Multiple Myeloma, Plasma Cell Neoplasm
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM.
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm, Malignant Plasma Cell Neoplasm
- Trial name
- NCT05336383
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Myeloma
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment.
- Conditions
- Lymphoma, Myeloma, Leukemia
- Trial name
- CHARKALL (NCT00881920)
- Testing
- Kappa CD28 T cells
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Baylor College of Medicine
Relapsed/Refractory Myeloma
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
- Trial name
- NCT06066359
- Testing
- Fludarabine phosphate, Cyclophosphamide, Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Plasma Cell Neoplasms
In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
This study aims to assess the safety profile of in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy in patients with relapsed or refractory plasma cell neoplasms.
- Trial name
- NCT07586709
- Testing
- In vivo BCMA/GPRC5D Tandem Dual CAR-T cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Liping Dou
Blood Cancers, Blood Cancer
Rutgers University Study of the Genetics of Blood Cancers
The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct…
- Conditions
- Blood Cancers, Blood Cancer, Leukemia, Lymphoma
- Trial name
- NCT07714044
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Elranatamab, Myeloma
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
The purpose of this study is to understand the study medicine (called Elranatamab, or PF-06863135) as potential treatment for refractory multiple myeloma.
- Conditions
- Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma
- Trial name
- NCT05228470
- Testing
- Elranatamab
- Where
- 15 sites in China
- Volunteers
- 39 people
- Sponsor
- Pfizer
Plasma Cell Myeloma, Transplant-Related Carcinoma
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies the safety of alternating ixazomib citrate and lenalidomide as treatment to help keep cancer from coming back after stem cell transplant (maintenance therapy) in treating patients with multiple…
- Trial name
- NCT02619682
- Testing
- Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto